|

Talquetamab Clinical Trials

17 actively recruiting trials across 12 locations

Also known as: Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, DuoBody Antibody JNJ-64407564, GPRC5D x CD3 Bispecific Antibody JNJ-64407564, GPRC5D x CD3 DuoBody Antibody JNJ-64407564, GPRC5D/CD3 DuoBody Antibody JNJ-64407564 +8 more

Pipeline

Phase 1: 2Phase 2: 11Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Janssen Research & Development, LLC4
  • University of Heidelberg Medical Center1
  • Stanford University1
  • St. Olavs Hospital1
  • SCRI Development Innovations, LLC1

Indications

  • Cancer17
  • Multiple Myeloma12
  • Refractory Multiple Myeloma3
  • Relapse Multiple Myeloma2
  • Post Stem Cell Transplant1

Other4 trials

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Phase 2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Phase 2
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
Phase 2
The Norwegian Immunotherapy in Multiple Myeloma Study

San Francisco, California2 trials

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

University of California San Francisco

Phase 2
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

University of Calfornia, San Francisco

Phase 1

Birmingham, Alabama1 trial

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama Birmingham

Phase 2

Gilbert, Arizona1 trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3

Tucson, Arizona1 trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Arizona Oncology Associates

Phase 2

Clovis, California1 trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

UCSF Fresno

Phase 3

Duarte, California1 trial

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

City of Hope Medical Center

Phase 1/2

Palo Alto, California1 trial

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Stanford University

Phase 2

New Haven, Connecticut1 trial

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Yale University

Phase 2

Miami, Florida1 trial

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

University of Miami

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

New York, New York1 trial

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Icahn School of Medicine at Mount Sinai

Phase 2

Milwaukee, Wisconsin1 trial

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Froedtert & the Medical College of Wisconsin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.